



GMP Manufacturing of Oral Aspirin Spray Dry Dispersion and Encapsulation

Contract # MBI-2212A (v4)

05 Jan 2023

Agenda


- Safety
- Background information
- Analytical development
- Lab scale spray drying prototype
- SDD GMP manufacture and encapsulation

1. Safety

- ❑ Compound OHC assessment to be provided.

2. Background information

- Current technology in producing Aspirin-Curcumin-PVP dispersion



* Aspirin: Curcumin: PVP-K30 (1:2:10 w/w)

3. Analytical

1. Assay and Impurities — Method Evaluation

- Evaluate USP method for Aspirin Tablets
- Verify chromatography—one run using existing API/reference standards and column

2. Assay and Impurities - Method Validation

- Generate Validation Protocol
- Evaluate specificity, linearity, accuracy and precision, LOD and LOQ; one analyst, one run
- Sample and Reference Standard Stability – up to 3 days
- Issue Analytical Test Method and Statement of Success
- (Optional) Method Validation Report

3. Water Content by Karl Fischer — Method Adaptation

- Optimize Sample Prep
- Evaluate the method per USP <921> Method 1c and BioDuro SOP

4. Residual solvent by GC — Method Adaptation

- Determine sample preparation and optimum GC conditions for analysis of residual solvents in per USP <467> or BioDuro method

3. Analytical

5. Equipment Cleaning Verification — Method Development

- Evaluate API recovery from API contaminated and cleaned metal and glass coupons to determine limit of cleaning and recovery
- Determine LOD and LOQ
- Single API/impurity, existing HPLC or TOC method

6. Equipment Cleaning Verification — Method Development

- Evaluate API recovery from API contaminated and cleaned metal and glass coupons to determine limit of cleaning and recovery
- Determine LOD and LOQ
- Single API/impurity, existing HPLC or TOC method

4. Process Development of Oral Aspirin Spray Dry Dispersion (SDD)

1. Generation of Process Development Protocol

2. Prepare SDD Prototypes on B-290 Spray Dryer

- Prepare up to 10 – 20 g SDD prototype
- Evaluation and optimization of process parameters using Client's formulation
- 1 process parameters

3. In-Process Testing of Process Development SDD Sample

- Number of samples: 1
- List of tests: Residual Solvents (GC), PSD, Bulk Density and Tap Density

4. Analytical Testing of Process Development SDD Sample

- Number of samples: 1
- List of tests: Assay/impurity

5. GMP Manufacture

1. Generation and Approval of Specifications

2. Release Testing of Raw Materials and API

3. Generation & Approval of 2 Master Batch Records -Manufacturing

4. Manufacture of GMP SDD

- Manufacture SDD on MS-35 for GMP Batch
- Process: Compounding, Spray Drying, Secondary Drying
- Batch size: up to 3 kg of SDD

6. Manufacture of Active Capsules

- Process: Encapsulation using Profill
- Number of Dosage Units: 3,000 capsules
- Bulk Package Final Product

5. In-Process Testing of SDD

- List of tests: Residual Solvents (GC), PSD, Tap and Bulk Density, Calculation of Flowability (Carr's Index)

7. In-process Testing of GMP Active Capsules

- Final Blend Sieve Particle Size
- Final Blend Uniformity

8. Analytical/Release Testing of SDD and Capsules

- List of tests: Assay/Impurities (HPLC), Water Content by Karl Fischer, MLT

Questions/Comments

1. **Specific supplier for Aspirin and Curcumin ?**
2. **In the current formulation is Curcumin fully soluble in Ethanol ? Acetone as alternative ?**
3. **Solid content will be adjusted for spray drying (10-20% solids).**

GMP Manufacturing of Oral Aspirin Spray Dry Dispersion and Encapsulation

Contract # MBI-2212A (v4)

01 Mar 2023

Buchi B290 Prototype

Ingredient	%w/w Solids	%w/w Solution
Aspirin	7.7	1.0
Curcumin	15.4	2.0
PVP K30 (Kollidon 30)	77.0	10.0
Tetrahydrofuran (THF)		71.1
Ethanol		15.9
Total weight	100.0	100.00

In-process parameters



Parameter	Set point
Inlet temperature	69-73 °C
Outlet Temperature	53 °C
Feed Rate*	5.6-6.0 g/min
Aspirator	100%
Nozzle Assembly	0.7 mm nozzle
Drying air flow	1744 L/h
Feed Solution Batch Size	700.0 g

Ingredient	Theoretical Quantity (g)
Aspirin	7.0
Curcumin	14.0
PVP K30 (Kollidon 30)	70.0
THF	497.7
Ethanol	111.3
Total weight (g)	700.0



- Wet yield of ~82% (~72g powder collected).
- Secondary drying completed at 40C under vacuum for 24 hours.
- Powder has poor flowability with electrostatic charge (expected from spray dried powders).


Buchi B290 Prototype- Testing (pXRD)



- pXRD diffractogram of the spray dried dispersion material shows no residual crystalline peaks indicative of amorphous nature of the components in the formulation

Buchi B290 Prototype- Testing (PSD and density)

- Bulk density of SDD was measured to be 0.22g/mL.
- Tapped density measured to be 0.42g/mL.



Trend					
	Record Number	Sample Name	Dx (10) (µm)	Dx (50) (µm)	Dx (90) (µm)
	10	ASPIRIN SDD_SUBLOT-1_PROMBI001_Trial 1	2.28	6.97	14.8
	11	ASPIRIN SDD_SUBLOT-1_PROMBI001_Trial 2	2.32	7.08	15.6
	Mean		2.30	7.03	15.2
	1xStd Dev		0.0277	0.0780	0.592
	1xRSD (%)		1.20	1.11	3.89

Next Steps

1. Lab scale assess/feasibility of SDD filling into capsules using Size 00 Profiller
2. Analytical testing of SDD material